[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX365733B - N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. - Google Patents

N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.

Info

Publication number
MX365733B
MX365733B MX2015006046A MX2015006046A MX365733B MX 365733 B MX365733 B MX 365733B MX 2015006046 A MX2015006046 A MX 2015006046A MX 2015006046 A MX2015006046 A MX 2015006046A MX 365733 B MX365733 B MX 365733B
Authority
MX
Mexico
Prior art keywords
trka kinase
thiourea
pyrrolidinyl
guanidine
pyrazolyl
Prior art date
Application number
MX2015006046A
Other languages
Spanish (es)
Other versions
MX2015006046A (en
Inventor
Allen Shelley
Kercher Timothy
R Kolakowski Gabrielle
J Brandhuber Barbara
Shannon L Winski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2015006046A publication Critical patent/MX2015006046A/en
Publication of MX365733B publication Critical patent/MX365733B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
MX2015006046A 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors. MX365733B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725913P 2012-11-13 2012-11-13
PCT/US2013/069729 WO2014078323A1 (en) 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2015006046A MX2015006046A (en) 2015-12-01
MX365733B true MX365733B (en) 2019-06-12

Family

ID=49667600

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006046A MX365733B (en) 2012-11-13 2013-11-12 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.
MX2019006834A MX2019006834A (en) 2012-11-13 2015-05-13 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019006834A MX2019006834A (en) 2012-11-13 2015-05-13 N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.

Country Status (32)

Country Link
US (2) US9896435B2 (en)
EP (2) EP3409670B1 (en)
JP (3) JP6316834B2 (en)
KR (1) KR102181915B1 (en)
CN (2) CN107857755B (en)
AU (2) AU2013344943B2 (en)
BR (1) BR112015010875B1 (en)
CA (1) CA2890876C (en)
CL (1) CL2015001261A1 (en)
CY (1) CY1120099T1 (en)
DK (1) DK2922844T3 (en)
ES (2) ES2834027T3 (en)
HK (1) HK1215438A1 (en)
HR (1) HRP20180331T1 (en)
HU (1) HUE038512T2 (en)
IL (1) IL238496B (en)
LT (1) LT2922844T (en)
ME (1) ME02990B (en)
MX (2) MX365733B (en)
MY (1) MY178262A (en)
NO (1) NO2876058T3 (en)
NZ (1) NZ708028A (en)
PH (1) PH12015500939B1 (en)
PL (1) PL2922844T3 (en)
PT (1) PT2922844T (en)
RS (1) RS57001B1 (en)
RU (1) RU2677667C2 (en)
SG (1) SG11201503728XA (en)
SI (1) SI2922844T1 (en)
UA (1) UA116455C2 (en)
WO (1) WO2014078323A1 (en)
ZA (1) ZA201503587B (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2464461T3 (en) 2008-09-22 2014-06-02 Array Biopharma, Inc. Imidazo [1,2B] pyridazine compounds substituted as inhibitors of TRK kinase
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
PL3205654T3 (en) 2010-05-20 2019-08-30 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
CN105130967B (en) 2011-05-13 2018-04-17 阵列生物制药公司 Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MX365733B (en) * 2012-11-13 2019-06-12 Array Biopharma Inc N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
CN104903310B (en) 2012-11-13 2018-08-14 阵列生物制药公司 It can be used for treating bicyclic urea, thiocarbamide, guanidine and the cyanoguandine compounds of pain
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
JP6453231B2 (en) 2013-11-28 2019-01-16 杏林製薬株式会社 Urea derivative or pharmacologically acceptable salt thereof
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
WO2016021629A1 (en) 2014-08-06 2016-02-11 塩野義製薬株式会社 Heterocyclic and carbocyclic derivative having trka-inhibiting activity
RS64122B1 (en) 2014-11-16 2023-05-31 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
KR20180021745A (en) 2015-06-01 2018-03-05 록쏘 온콜로지, 인코포레이티드 How to diagnose and treat cancer
EP3330256B1 (en) 2015-07-07 2021-06-16 Shionogi & Co., Ltd. HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
BR112018000808A2 (en) 2015-07-16 2018-09-04 Array Biopharma Inc substituted pyrazolo [1,5-a] pyridine compounds as retinase inhibitors
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10533006B2 (en) 2016-02-04 2020-01-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
BR112018070017A2 (en) 2016-04-04 2019-02-05 Loxo Oncology Inc Pediatric Cancer Treatment Methods
MX2018012163A (en) 2016-04-04 2019-07-08 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrro lidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
JP2019026646A (en) * 2017-08-03 2019-02-21 塩野義製薬株式会社 Pharmaceutical composition for treating or preventing pain, containing nitrogen-containing heterocyclic and carbocyclic derivative
ES2967094T3 (en) 2017-09-29 2024-04-26 Mitsubishi Tanabe Pharma Corp Optically active pyrrolidine compound and production process thereof
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
MA50456A (en) 2017-10-26 2020-09-02 Array Biopharma Inc MACROCYCLIC KINASE TRK INHIBITOR FORMULATIONS
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
CN111971286B (en) 2018-01-18 2023-04-14 阿雷生物药品公司 Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors
TWI804585B (en) 2018-03-05 2023-06-11 美商必治妥美雅史谷比公司 Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
WO2020011227A1 (en) * 2018-07-12 2020-01-16 南京明德新药研发有限公司 Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN110964016B (en) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 Amino-norbornane derivative and preparation method and application thereof
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
BR112021018168B1 (en) 2019-03-21 2023-11-28 Onxeo PHARMACEUTICAL COMPOSITION, COMBINATION AND KIT COMPRISING A DBAIT MOLECULE AND A KINASE INHIBITOR FOR THE TREATMENT OF CANCER
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN112979615B (en) * 2019-12-17 2024-08-09 上海医药集团股份有限公司 Quinazoline urea compound, preparation method thereof, preparation intermediate, pharmaceutical composition and application
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022218289A1 (en) * 2021-04-12 2022-10-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
CN113278409B (en) * 2021-06-22 2022-04-29 西南石油大学 High-temperature acidizing corrosion inhibitor
CN114031556B (en) * 2021-11-08 2023-03-31 温州大学 Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method
WO2024061768A1 (en) 2022-09-19 2024-03-28 Basf Se Azole pesticidal compounds

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679887B2 (en) 1995-09-11 1997-07-10 Nihon Nohyaku Co., Ltd. Azole derivatives, their use, production and usage
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EP1028953A1 (en) 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
AU762077B2 (en) 1997-12-22 2003-06-19 Bayer Healthcare Llc Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
MXPA00006233A (en) 1997-12-22 2002-09-18 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS.
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
DE69926542T2 (en) 1998-12-25 2006-04-27 Teikoku Hormone Mfg. Co., Ltd. aminopyrazole
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6410533B1 (en) 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
CN1440402A (en) 2000-06-30 2003-09-03 布里斯托尔-迈尔斯斯奎布公司 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
WO2003037274A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
JP2005518365A (en) 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド 4-aminoquinoline compounds
SE0104248D0 (en) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
US7157472B2 (en) 2002-07-02 2007-01-02 Schering Corporation Neuropeptide Y Y5 receptor antagonists
PL211654B1 (en) 2002-10-08 2012-06-29 Rinat Neuroscience Corp Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2005024755A2 (en) 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
ATE510824T1 (en) 2003-06-12 2011-06-15 Abbott Lab CONDENSED COMPOUNDS THAT INHIBIT THE VANILLOID RECEPTOR SUBTYPE-1
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
JP4573223B2 (en) 2004-01-23 2010-11-04 東レ・ファインケミカル株式会社 Process for producing optically active trans-4-amino-1-benzyl-3-pyrrolidinol
CN101010315A (en) 2004-04-30 2007-08-01 拜耳制药公司 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
EP1831228A1 (en) 2004-12-20 2007-09-12 AstraZeneca AB Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
AU2005325676A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
WO2007059202A2 (en) 2005-11-15 2007-05-24 Bayer Healthcare Ag Pyrazolyl urea derivatives useful in the treatment of cancer
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2631746A1 (en) 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
EP2049542B1 (en) 2006-08-09 2012-09-19 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
BRPI0807717A2 (en) 2007-04-20 2014-05-20 Deciphera Pharmaceuticals Llc KINASE INHIBITORS USEFUL FOR TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES.
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
ITMI20071731A1 (en) 2007-09-06 2009-03-07 Univ Degli Studi Genova NEW UREIC DERIVATIVES OF 1H-PIRAZOL-4-CARBOXYLIC ACID WITH INHIBITIVE ACTIVITY TOWARDS NEUTRROPHILES CHEMOTASSASSES
KR101324804B1 (en) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US8592454B2 (en) 2008-09-19 2013-11-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
ES2464461T3 (en) 2008-09-22 2014-06-02 Array Biopharma, Inc. Imidazo [1,2B] pyridazine compounds substituted as inhibitors of TRK kinase
EP2331500A1 (en) 2008-10-09 2011-06-15 F. Hoffmann-La Roche AG Pyrrolidine n-benzyl derivatives
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
ES2605811T3 (en) 2008-11-19 2017-03-16 Merial, Inc. Dimeric 1-arylpyrazole derivatives
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
CN102264737A (en) 2008-12-23 2011-11-30 雅培制药有限公司 Anti-viral compounds
EP2398323A4 (en) 2009-02-19 2012-08-08 Univ Connecticut Novel hetero pyrrole analogs acting on cannapinoid receptors
US20120071475A1 (en) 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
AR077468A1 (en) * 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
CA2771612A1 (en) 2009-09-18 2011-03-24 Zalicus Pharmaceuticals Ltd. Selective calcium channel modulators
PL3205654T3 (en) 2010-05-20 2019-08-30 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
WO2012129258A1 (en) * 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
CN105130967B (en) * 2011-05-13 2018-04-17 阵列生物制药公司 Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
EP2900223B1 (en) 2012-09-28 2017-10-25 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX2015004041A (en) 2012-09-28 2015-07-06 Merck Sharp & Dohme Novel compounds that are erk inhibitors.
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MX365733B (en) * 2012-11-13 2019-06-12 Array Biopharma Inc N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.
CN104903310B (en) 2012-11-13 2018-08-14 阵列生物制药公司 It can be used for treating bicyclic urea, thiocarbamide, guanidine and the cyanoguandine compounds of pain
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
RS57001B1 (en) 2018-05-31
JP2019081786A (en) 2019-05-30
US10851080B2 (en) 2020-12-01
BR112015010875A8 (en) 2019-10-01
CN107857755B (en) 2020-10-27
JP6482629B2 (en) 2019-03-13
BR112015010875A2 (en) 2017-07-11
PH12015500939A1 (en) 2015-06-29
MY178262A (en) 2020-10-07
NO2876058T3 (en) 2018-06-30
PL2922844T3 (en) 2018-06-29
RU2677667C2 (en) 2019-01-18
BR112015010875B1 (en) 2022-05-03
CA2890876C (en) 2021-01-19
ES2664331T3 (en) 2018-04-19
DK2922844T3 (en) 2018-03-05
SG11201503728XA (en) 2015-06-29
MX2019006834A (en) 2019-09-06
CL2015001261A1 (en) 2015-09-25
CN107857755A (en) 2018-03-30
WO2014078323A1 (en) 2014-05-22
KR20150084047A (en) 2015-07-21
RU2015122414A (en) 2017-01-10
AU2017206195B2 (en) 2019-01-03
PH12015500939B1 (en) 2015-06-29
UA116455C2 (en) 2018-03-26
IL238496A0 (en) 2015-06-30
US9896435B2 (en) 2018-02-20
HK1215438A1 (en) 2016-08-26
JP6316834B2 (en) 2018-04-25
NZ708028A (en) 2018-12-21
EP2922844A1 (en) 2015-09-30
IL238496B (en) 2018-02-28
EP3409670A1 (en) 2018-12-05
HRP20180331T1 (en) 2018-05-04
ES2834027T3 (en) 2021-06-16
US20160280682A1 (en) 2016-09-29
EP3409670B1 (en) 2020-09-09
AU2017206195A1 (en) 2017-08-03
ZA201503587B (en) 2020-11-25
PT2922844T (en) 2018-04-02
AU2013344943A1 (en) 2015-06-04
JP2018048176A (en) 2018-03-29
CA2890876A1 (en) 2014-05-22
CY1120099T1 (en) 2018-12-12
LT2922844T (en) 2018-03-26
EP2922844B1 (en) 2018-01-10
CN104781255B (en) 2017-10-24
SI2922844T1 (en) 2018-04-30
JP2016501191A (en) 2016-01-18
MX2015006046A (en) 2015-12-01
HUE038512T2 (en) 2018-10-29
US20180179182A1 (en) 2018-06-28
KR102181915B1 (en) 2020-11-23
ME02990B (en) 2018-10-20
AU2013344943B2 (en) 2017-06-29
CN104781255A (en) 2015-07-15

Similar Documents

Publication Publication Date Title
MX2019006834A (en) N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors.
PH12015500938A1 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
MY173181A (en) Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
EA201891049A1 (en) ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS MNK1 AND MNK2
PH12018501073A1 (en) Eif4-a-inhibiting compounds and methods related thereto
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
EA201891050A1 (en) COMPOUNDS PYRROLO, PYRAZOLO, IMIDAZOPYRIMIDINE AND PYRIDINE THAT INHIBIT MNK1 AND MNK2
CL2015001374A1 (en) Compounds derived from 2- (methylamino) -n- (2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl) propanamide; pharmaceutical composition; and its use in the therapeutic or prophylactic treatment of cancer.
MX2017012926A (en) Inhibitors and their uses.
CR20110478A (en) PANCREAS CANCER TREATMENT
DOP2018000134A (en) 1,3,4-TIADIAZOL COMPOUNDS AND THEIR USE IN CANCER TREATMENT
CR20150300A (en) N-PIRROLIDINIL, N´-PIRAZOLIL-UREA, TIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS INHIBITORS OF TRKA CINASA
MD4402C1 (en) Methyl-N'-[(2-hydroxynaphthalene-1-il)methylidene]-N-prop-2-en-1-ylhydrazonothioate, exhibiting antifungal activity against Candida albicans

Legal Events

Date Code Title Description
FG Grant or registration